Please use this identifier to cite or link to this item:
Title: Pembrolizumab in relapsed or refractory Richter syndrome.
Authors: Armand, Philippe;Murawski, Niels;Molin, Daniel;Zain, Jasmine;Eichhorst, Barbara;Gulbas, Zafer;Hawkes, Eliza A;Pagel, John M;Phillips, Tycel;Ribrag, Vincent;Svoboda, Jakub;Stathis, Anastasios;Chatterjee, Arkendu;Orlowski, Robert;Marinello, Patricia;Christian, Beth
Affiliation: Dana-Farber Cancer Institute, Boston, MA, USA..
University of Cologne, Cologne, Germany
Anadolu Medical Center, Istanbul, Turkey
Universit├Ąts-klinikum des Saarlandes Innere Medizin I, Homburg, Germany
Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia
Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden..
City of Hope, Duarte, CA, USA..
Swedish Center for Blood Disorders and Stem Cell Transplants, Swedish Cancer Institute, Seattle, WA, USA..
Rogel Cancer Center, Ann Arbor, MI, USA..
Institut Gustave Roussy, Villejuif, France..
Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA, USA..
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland..
Merck & Co., Inc, Kenilworth, NJ, USA..
The James Cancer Hospital and Solove Research Institute, Ohio State University, Columbus, OH, USA..
Issue Date: 16-Jun-2020
EDate: 2020
Citation: British journal of haematology 2020; online first: 16 June
DOI: 10.1111/bjh.16762
ORCID: 0000-0001-6098-1603
PubMed URL: 32544980
Type: Letter
Subjects: PD-1
Richter syndrome
chronic lymphocytic leukaemia
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.

Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.